TXA vs. Amicar in Total Knee and Hip Arthroplasty
| Status: | Completed |
|---|---|
| Conditions: | Arthritis |
| Therapuetic Areas: | Rheumatology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/7/2018 |
| Start Date: | January 2015 |
| End Date: | November 12, 2017 |
TXA (Tranexamic Acid) vs. Amicar (Aminocaproic Acid) in Total Knee and Hip Arthroplasty- Effectiveness, Safety, and Cost Analysis
The purpose of this study is to determine the relative effectiveness of two drug agents,
Tranexamic acid (TXA) and aminocaproic acid (Amicar), that act through a similar mechanism of
action. These agents are used to decrease blood loss that is a result of major surgery, like
total joint arthroplasty. A secondary goal will be investigate the cost-analysis of total
hospitalization. Both TXA and Amicar are both currently used in the care of patients
undergoing total joint arthroplasty.
Subjects will be randomly assigned to the TXA or Amicar arm. All data needed for this study
including blood loss, need for transfusion, preoperative and lowest postoperative hematocrit
and hemoglobin, and complications will be collected during the hospitalization stay.
Our Hypothesis is that TXA and Amicar will have similar effectiveness in preventing
intraoperative blood loss and the need for transfusion post-op than Amicar.
A detailed cost analysis will show that the overall cost of performing the operative
procedure, including transfusions, OR time, and total costs associated with admission cost
will be more decreased with Amicar as compared to TXA.
Tranexamic acid (TXA) and aminocaproic acid (Amicar), that act through a similar mechanism of
action. These agents are used to decrease blood loss that is a result of major surgery, like
total joint arthroplasty. A secondary goal will be investigate the cost-analysis of total
hospitalization. Both TXA and Amicar are both currently used in the care of patients
undergoing total joint arthroplasty.
Subjects will be randomly assigned to the TXA or Amicar arm. All data needed for this study
including blood loss, need for transfusion, preoperative and lowest postoperative hematocrit
and hemoglobin, and complications will be collected during the hospitalization stay.
Our Hypothesis is that TXA and Amicar will have similar effectiveness in preventing
intraoperative blood loss and the need for transfusion post-op than Amicar.
A detailed cost analysis will show that the overall cost of performing the operative
procedure, including transfusions, OR time, and total costs associated with admission cost
will be more decreased with Amicar as compared to TXA.
Inclusion Criteria:
- Patients electing to undergo primary total hip or knee arthroplasty
Exclusion Criteria:
- History of stents
- Myocardial infarction,
- Cerebrovascular accident or stroke
- Deep venous thrombus
- Pulmonary embolus
- Late onset color blindness
- Hypercoagulable state
We found this trial at
1
site
2301 Erwin Rd
Durham, North Carolina 27710
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Michael P Bolognesi, MD
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
